Literature DB >> 17325102

Coverage and prior authorization of psychotropic drugs under Medicare Part D.

Haiden A Huskamp1, David G Stevenson, Julie M Donohue, Joseph P Newhouse, Nancy L Keating.   

Abstract

This study examined formulary coverage and use of utilization management tools for three classes of psychotropic medications (antidepressants, antipsychotics, and anticonvulsants) among Medicare Part D prescription drug plans serving individuals dually eligible for the Medicare and Medicaid programs. Plans must cover "all or substantially all" molecules (distinct drugs) in these classes. Plans serving "dual eligibles" generally covered at least one formulation of all molecules in the three classes. However, certain product formulations were not covered by a number of plans, and use of prior authorization was common for a minority of plans. The effect of Part D will depend on the restrictiveness of the prior authorization and appeals processes, which is currently unknown.

Mesh:

Substances:

Year:  2007        PMID: 17325102     DOI: 10.1176/ps.2007.58.3.308

Source DB:  PubMed          Journal:  Psychiatr Serv        ISSN: 1075-2730            Impact factor:   3.084


  12 in total

1.  Association between prior authorization for medications and health service use by Medicaid patients with bipolar disorder.

Authors:  Christine Y Lu; Alyce S Adams; Dennis Ross-Degnan; Fang Zhang; Yuting Zhang; Carl Salzman; Stephen B Soumerai
Journal:  Psychiatr Serv       Date:  2011-02       Impact factor: 3.084

2.  Coverage of atypical antipsychotics among medicare drug plans in the state of washington: changes between 2007 and 2008.

Authors:  Meng-Yun Wu; Jae Kennedy; Lawrence J Cohen; Chi-Chuan Wang
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2009

Review 3.  Medicare Part D's effect on the under- and overuse of medications: a systematic review.

Authors:  Jennifer M Polinski; Julie M Donohue; Elaine Kilabuk; William H Shrank
Journal:  J Am Geriatr Soc       Date:  2011-08-01       Impact factor: 5.562

4.  Effect of Part D coverage restrictions for antidepressants, antipsychotics, and cholinesterase inhibitors on related nursing home resident outcomes.

Authors:  David G Stevenson; A James O'Malley; Stacie B Dusetzina; Susan L Mitchell; Barbara J Zarowitz; Michael E Chernew; Joseph P Newhouse; Haiden A Huskamp
Journal:  J Am Geriatr Soc       Date:  2014-08-14       Impact factor: 5.562

5.  Restrictive reimbursement policies: bias implications for claims-based drug safety studies.

Authors:  Joshua J Gagne
Journal:  Drug Saf       Date:  2014-10       Impact factor: 5.606

6.  Changes in drug coverage generosity and untreated serious mental illness: transitioning from Medicaid to Medicare Part D.

Authors:  Jeanne M Madden; Alyce S Adams; Robert F LeCates; Dennis Ross-Degnan; Fang Zhang; Haiden A Huskamp; Daniel M Gilden; Stephen B Soumerai
Journal:  JAMA Psychiatry       Date:  2015-02       Impact factor: 21.596

7.  Medicare formulary coverage for top-selling biologics.

Authors:  Su-Ying Liang; Jennifer S Haas; Kathryn A Phillips
Journal:  Nat Biotechnol       Date:  2009-12       Impact factor: 54.908

8.  Coverage of atypical antipsychotics among medicare drug plans in the state of washington for fiscal year 2007.

Authors:  Chi-Chuan Wang; Jae Kennedy; Lawrence J Cohen; David A Sclar
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2008

9.  Prior authorization for antidepressants in Medicaid: effects among disabled dual enrollees.

Authors:  Alyce S Adams; Fang Zhang; Robert F LeCates; Amy Johnson Graves; Dennis Ross-Degnan; Daniel Gilden; Thomas J McLaughlin; Christine Lu; Connie M Trinacty; Stephen B Soumerai
Journal:  Arch Intern Med       Date:  2009-04-27

10.  Part D and dually eligible patients with mental illness: medication access problems and use of intensive services.

Authors:  Haiden A Huskamp; Joyce C West; Donald S Rae; Maritza Rubio-Stipec; Darrel A Regier; Richard G Frank
Journal:  Psychiatr Serv       Date:  2009-09       Impact factor: 3.084

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.